

Early detection of GA and timely referral may help maintain the quality of vision patients deserve for longer.¹

Considerations for Identifying and Selecting Patients for Referral



Retinal Imaging: Plays a Critical Role in Early GA Diagnosis

OCT is helpful in identifying hallmark biomarkers of GA²

- What to look for³:
 - Zone(s) of attenuation or disruption of the RPE
 - Presence of choroidal hypertransmission
 - Evidence of overlying photoreceptor degeneration

FAF is helpful for assessing lesion size and monitoring disease progression^{2,4}

- What to look for^{5,6}:
 - Areas of hypoautofluorescence with sharply demarcated borders
 - Patterns of hyperautofluorescence surrounding atrophic lesions such as focal, patchy, banded, diffuse, or diffuse-trickling

CFP is useful in establishing a baseline of the disease and monitoring progression²

- What to look for^{4,5,7}:
 - Drusen as well as depigmentation and hyperpigmentation of areas of the fundus
 - Hypopigmented GA lesion with sharply demarcated areas with increased choroidal vessel visibility



Functional Visual Assessments

Visual acuity often does not provide a complete assessment of visual function. A decline in visual function can lead to a decline in quality of life.^{4,8-10} It's important to inquire about:

- Trouble performing daily activities (reading, driving, hobbies, etc.)^{8,10,11}
- Difficulty with low-light vision, night vision, or driving in low-light conditions^{4,5,12}
- Decreased contrast sensitivity¹²
- Decreased reading speed¹²



Lesion Characteristics Associated With Faster Progression Rates

GA is a heterogenous disease, and factors of its presentation may be associated with a faster progression rate.⁵ These factors can include:

- Non-foveal lesions⁵
- Multifocal lesions⁵
- Bilateral disease¹³


Patient Discussion and Education



Educate your patients on what they may expect throughout their GA journey.

- Explain the irreversible impact GA may have on vision
- Discuss the goal of future treatment and management is to slow disease progression
- Emphasize the importance of regular monitoring and follow-up appointments

Partnering With Your Eye Care Colleagues



Early alignment with your eye care colleagues can help ensure optimal outcomes for your patients.

Discuss with your retinal specialist partner:

- Which patients to refer and when in their course of disease to take action
- The appropriate information to share, such as previous imaging scans, functional vision changes, patient history, and proper coding based on disease presentation
- How you can collaborate to optimize patient management

**Identify and flag patients with GA now
for future referral and management considerations.**



Scan here for additional information on patient referral and management or visit seeGAdifferently.com/refer

CFP=color fundus photography; FAF=fundus autofluorescence; OCT=optical coherence tomography; RPE=retinal pigment epithelium.

References: 1. Flaxel CJ, Adelman RA, Bailey ST, et al. Age-related macular degeneration preferred practice pattern(R). *Ophthalmology*. 2020;127(1):P1-P65. 2. Holz FG, Sadda SR, Staurengi G, et al. Imaging protocols in clinical studies in advanced age-related macular degeneration: recommendations from Classification of Atrophy Consensus Meetings. *Ophthalmology*. 2017;124(4):464-478. 3. Guymer RH, Rosenfeld PJ, Curcio CA, et al. Incomplete retinal pigment epithelial and outer retinal atrophy in age-related macular degeneration: classification of atrophy meeting report 4. *Ophthalmology*. 2020;127(3):394-409. 4. Sadda SR, Chakravarthy U, Birch DG, et al. Clinical endpoints for the study of geographic atrophy secondary to age-related macular degeneration. *Retina*. 2016;36(10):1806-1822. 5. Fleckenstein M, Mitchell P, Freund KB, et al. The progression of geographic atrophy secondary to age-related macular degeneration. *Ophthalmology*. 2018;125(3):369-390. 6. Yung M, Klufas MA, Sarraf D. Clinical applications of fundus autofluorescence in retinal disease. *Int J Retina Vitreous*. 2016;2:12. 7. Garrity ST, Sarraf D, Freund KB, Sadda SR. Multimodal imaging of nonneovascular age-related macular degeneration. *Invest Ophthalmol Vis Sci*. 2018;59(4):AMD48-AMD64. 8. Carlton J, Barnes S, Haywood A. Patient perspectives in geographic atrophy (GA): exploratory qualitative research to understand the impact of GA for patients and their families. *Br J Ophthalmol*. 2019;103(1):133-141. 9. Sivaprasad S, Tschosik EA, Guymer RH, et al. Living with geographic atrophy: an ethnographic study. *Ophthalmol Ther*. 2019;8(1):115-124. 10. Singh RP, Patel SS, Nielsen JS, Schmier JK, Rajput Y. Patient-, caregiver-, and eye care professional-reported burden of geographic atrophy secondary to age-related macular degeneration. *Am J Ophthalmol Clin Trials*. 2019;2(1):1-6. 11. Patel PJ, Ziemssen F, Ng E, et al. Burden of illness in geographic atrophy: a study of vision-related quality of life and health care resource use. *Clin Ophthalmol*. 2020;14:15-28. 12. Sunness JS, Rubin GS, Applegate CA, et al. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. *Ophthalmology*. 1997;104(10):1677-1691. 13. Grassmann F, Fleckenstein M, Chew EY, et al. Clinical and genetic factors associated with progression of geographic atrophy lesions in age-related macular degeneration. *PLoS One*. 2015;10(5):e0126636.

SEE GA DIFFERENTLY

